| 引用本文: |
郭婉婕,官海静,刘国恩,等.蒽环类药物联用右雷佐生治疗乳腺癌的药物经济学评价[J].中国卫生经济,2017,(7):75-78.[点击复制] |
.The Pharmacoeconomic Evaluation of Anthracyclines Combined with Dexrazoxane for Breast Cancer[J].CHINESE HEALTH ECONOMICS,2017,(7):75-78.[点击复制] |
|
| 摘要: |
| 目的：对蒽环类药物联用右雷佐生（又称右丙亚胺）治疗乳腺癌进行药物经济学评价。方法：从支付方角度出发，采用Markov模型，对于蒽环类药物联用右雷佐生（试验组）和不联用右雷佐生（对照组）两种乳腺癌治疗方案进行终身的成本效用分析。成本参数来源于广东地区的医院抽样数据，概率参数和效用参数来源于文献，循环周期为1年，并进行了敏感性分析。结果：试验组和对照组的终身直接医疗费用分别为12.59万元和12.49万元，质量调整生命年分别为12.861QALYs和12.345QALYs。试验组的效果更好，同时费用更高。基础分析结果显示增量成本效果比（ICER）为2075元/QALY，远低于2015年中国3倍人均GDP（148053元），敏感性分析显示了研究结果的稳健性。结论：从长期来看，对于乳腺癌患者，相比单用蒽环类药物方案，联用右雷佐生治疗乳腺癌的同时，降低了心力衰竭的发生率，更具有成本效果优势。 |
| 关键词: |
| DOI： |
|
| 基金项目: |
|
| The Pharmacoeconomic Evaluation of Anthracyclines Combined with Dexrazoxane for Breast Cancer |
|
| () |
| Abstract: |
| Objective: To conduct a pharmacoeconomic evaluation of anthracyclines combined with dexrazoxane for breast cancer. Methods: The cost utility analysis based on Markov model was conducted to compare the anthracyclines combined with dexrazoxane(treatment group ) and anthracyclines alone(control group) from the perspective of payer. The cost parameters were derived from hospital sampling data in Guangdong province, and the probability and utility parameters were from literature review. The cycle length is 1 year. The sensitivity analysis is also performed. Results: The lifetime cost of cumulative direct medical in treatment group and control group was 125.9 thousand yuan and 124.9 thousand yuan, and the quality adjusted life year was 12.861QALYs and 12.345QALYs respectively. The treatment group had better effect with higher cost. The basic analysis indicated that the incremental cost effectiveness ratio (ICER) was 2075 Yuan/QALY, which was lower than 3 times of China GDP per capita in 2015(148053Yuan). The sensitivity analysis showed the robustness of results. Conclusion: Anthracyclines combined with dexrazoxane can reduce the incidence of heart failure and have cost effectiveness compared with the anthracyclines alone for breast cancer in long term. |
| Key words: |
